MC-V declares no COI. MS declares no COI. CC has received honoraria from AbbVie. PSesques has received honoraria from AbbVie, BMS, Chugai, Janssen, Kite/Gilead, Novartis and Roche. MR declares no COI. PB has received honoraria from Abbvie, Beigene, BMS, Novartis, Kyte-Gilead, Servier. VA declares no COI. AO declares no COI. IDB declares no COI. AV declares no COI. CB declares advisory fees from JNJ, BMS, BeiGene, Abbvie, Cureety (consulting); JNJ, BeiGene (honoraria); from Institut Servier (research funding). PStephan. LV has received honoraria from Kite/Gilead, acted as consultant for Pixilib and Genmab; received hospitality from MSD France, Siemens Healthcare and Sanofi Aventis. FV declares no COI. RP declares no COI. RH has received honoraria from Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, Incyte, Janssen, MSD, Takeda, Amgen, Abbvie, and Roche; and is a member on an entity’s Board of Directors or advisory committees of Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, Tessa Therapeutics, Abbvie and Roche. RDJ declares no COI. IS declares no COI. NP declares no COI. ACB declares no COI. JL declares no COI. MM: declares no COI. RDB has received honoraria from Kite/Gilead, Novartis, BMS, Amgen, Abbvie and Roche. SC-Z: declares no COI. CT: reports membership on an entity’s Board of Directors or advisory committees of Kite, Amgen, AbbVie, Novartis, Roche, Gilead, Takeda, BMS/Celgene, Incyte, and Cellectis; consultancy for Kite, Amgen, AbbVie, Novartis, Gilead, Cellectis, Roche, and BMS/Celgene; honoraria from Takeda, Incyte, Bayer, Kite, Gilead, Novartis, BMS, Abbvie, F. Hoffmann-La Roche Ltd, Amgen, Cellectis, and Janssen; research funding from Hospira and BMS/Celgene; and support for attending meetings and/or travel from Kite Pharma / Gilead, Amgen, AbbVie, Novartis, Gilead, Cellectis, Roche, BMS/Celgene, and Janssen.